Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
Double blind placebo-controlled Phase I/II clinical trial of idebenone in patients with primary progressive multiple sclerosis (IPPoMS)
B-cell depletion in vitro and in vivo with an afucosylated anti-CD19 antibody.
A genome screen for multiple sclerosis in Italian families.
Suppression of Murine Experimental Autoimmune Optic Neuritis by Mature Dendritic Cells Transfected with Calcitonin Gene-Related Peptide Gene.
Associations of CD6, TNFRSF1A, and IRF8 polymorphisms with risk of inflammatory demyelinating diseases.
Meralgia paresthetica after subcutaneous injection of glatiramer acetate.
Associations between changes in ferritin levels and susceptibility-weighted imaging filtered phase in patients with relapsing-remitting multiple sclerosis over 24weeks of therapy with subcutaneous interferon beta-1a three times weekly.
Fingolimod phosphate promotes the neuroprotective effects of microglia.
Treatment of multiple sclerosis with anti-CD20 antibodies.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
The effect of the interval-between-sessions on prefrontal transcranial direct current stimulation (tDCS) on cognitive outcomes: a systematic review and meta-analysis.
A comparative study of experimental mouse models of central nervous system demyelination.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
The Effect of Three Times a Week Glatiramer Acetate on Cerebral T1 Hypointense Lesions in Relapsing-Remitting Multiple Sclerosis.
Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis.
Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Pfizer and Synthon Enter Into U.S. Commercialization Agreement for Potential Generic Treatment of Multiple Sclerosis
Disease Modifying Potential of Glatiramer Acetate in Huntington's Disease.
The antioxidant idebenone fails to prevent or attenuate chronic experimental autoimmune encephalomyelitis in the mouse.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015

Pages